Literature DB >> 12813200

99mTc galactosyl human serum albumin liver dynamic SPET for pre-operative assessment of hepatectomy in relation to percutaneous transhepatic portal embolization.

Y Nishiyama1, Y Yamamoto, I Hino, K Satoh, H Wakabayashi, M Ohkawa.   

Abstract

We have devised an original predictive residual index (PRI) using 99mTc diethylenetriaminepentaacetic acid galactosyl human serum albumin (99mTc-GSA) liver dynamic SPET for the pre-operative assessment of hepatectomy, including the prediction of residual liver function before hepatectomy. The aim of this study was to evaluate the usefulness of the PRI by using 99mTc-GSA liver dynamic SPET before and after percutaneous transhepatic portal embolization (PTPE) to induce compensatory hypertrophy of the remnant lobe, and to compare the results with the prognosis after hepatectomy. The subjects included eight patients with cholangiocellular carcinoma, five with gallbladder cancer, four with hepatocellular carcinoma and three with metastatic liver cancer. 99mTc-GSA liver dynamic SPET was performed immediately before and 2 weeks after PTPE. Dynamic SPET with 35 continuous rotations was performed to obtain the k-value according to the accumulation curve in each voxel (0.54 cm x 0.54 cm x 1.08 cm) of the liver immediately after a bolus injection of 185 MBq 99mTc-GSA. Each rotation consisted of 180 degrees turn in 64 steps in a 64 x 64 matrix. The acquisition time of each rotation was 35 s. We devised an original PRI by combining the k-value with functional liver volume which were measured by liver dynamic SPET. Hepatectomy was performed following the second SPET. The correlation between the PRI and post-operative patient prognosis was investigated retrospectively. The functional liver volume of the remnant lobe and the PRI significantly increased after PTPE compared with respective values before PTPE (P<0.005 and P<0.0001, respectively). Regarding the relationship between the PRI and the clinical course following surgery, post-operative complications were observed in only two patients. The PRI values of these two patients were 0.323 and 0.394. When the PRI was above 0.400, no patient had symptoms of hepatic failure. The results of this study suggest that, when the PRI value is above 0.400, there is a low probability of hepatic failure after hepatectomy. We conclude that the PRI devised in this study is useful in the pre-operative assessment of hepatectomy after PTPE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12813200     DOI: 10.1097/00006231-200307000-00011

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  14 in total

1.  Preliminary study on liver function changes after trisectionectomy with versus without prior portal vein embolization.

Authors:  Maciej Malinowski; Johan Friso Lock; Daniel Seehofer; Bernhard Gebauer; Antje Schulz; Lina Demirel; Jan Bednarsch; Victoria Stary; Peter Neuhaus; Martin Stockmann
Journal:  Surg Today       Date:  2015-12-31       Impact factor: 2.549

Review 2.  Portal vein embolization before liver resection: a systematic review.

Authors:  K P van Lienden; J W van den Esschert; W de Graaf; S Bipat; J S Lameris; T M van Gulik; O M van Delden
Journal:  Cardiovasc Intervent Radiol       Date:  2012-07-18       Impact factor: 2.740

3.  Hepatic function assessment to predict post-hepatectomy liver failure: what can we trust? A systematic review.

Authors:  Federico Tomassini; Mariano C Giglio; Giuseppe De Simone; Roberto Montalti; Roberto I Troisi
Journal:  Updates Surg       Date:  2020-08-04

4.  Factors influencing hypertrophy of the left lateral liver lobe after portal vein embolization.

Authors:  Maciej Malinowski; Victoria Stary; Johan F Lock; Antje Schulz; Maximilian Jara; Daniel Seehofer; Bernhard Gebauer; Timm Denecke; Dominik Geisel; Peter Neuhaus; Martin Stockmann
Journal:  Langenbecks Arch Surg       Date:  2015-01-06       Impact factor: 3.445

5.  Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis.

Authors:  Fang Zheng; Amanda Sparkes; Patrick De Baetselier; Steve Schoonooghe; Benoit Stijlemans; Serge Muyldermans; Véronique Flamand; Jo A Van Ginderachter; Nick Devoogdt; Geert Raes; Alain Beschin
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

6.  Improved liver function after portal vein embolization and an elective right hepatectomy.

Authors:  Raphael P H Meier; Christian Toso; Sylvain Terraz; Romain Breguet; Thierry Berney; Axel Andres; Anne-Sophie Jannot; Laura Rubbia-Brandt; Philippe Morel; Pietro E Majno
Journal:  HPB (Oxford)       Date:  2015-09-08       Impact factor: 3.647

Review 7.  Current Modalities for the Assessment of Future Remnant Liver Function.

Authors:  Fadi Rassam; Pim B Olthof; Roelof J Bennink; Thomas M van Gulik
Journal:  Visc Med       Date:  2017-11-30

Review 8.  Resection for Klatskin tumors: technical complexities and results.

Authors:  Ivan Capobianco; Jens Rolinger; Silvio Nadalin
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-18

Review 9.  Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma.

Authors:  Toru Beppu; Kensuke Yamamura; Hirohisa Okabe; Katsunori Imai; Hiromitsu Hayashi
Journal:  Ann Gastroenterol Surg       Date:  2020-12-13

Review 10.  Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine.

Authors:  Liang Wang
Journal:  Hepat Med       Date:  2010-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.